Laurence Klotz

Summary

Affiliation: Sunnybrook Health Sciences Centre
Country: Canada

Publications

  1. ncbi Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Semin Radiat Oncol 18:2-6. 2008
  2. ncbi What is the best approach for screen-detected low volume cancers?--The case for observation
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Urol Oncol 26:495-9. 2008
  3. ncbi Combined androgen blockade: an update
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Urol Clin North Am 33:161-6, v-vi. 2006
  4. ncbi Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 109:858-67. 2007
  5. doi Maximal androgen blockade for advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada
    Best Pract Res Clin Endocrinol Metab 22:331-40. 2008
  6. pmc Active surveillance for favorable-risk prostate cancer: a short review
    Nathan Lawrentschuk
    Department of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada
    Korean J Urol 51:665-70. 2010
  7. pmc Active surveillance for low-risk prostate cancer
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre 2075 Bayview Ave MG 408, Toronto Ontario M4N3M5
    F1000 Med Rep 4:16. 2012
  8. doi Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, 2075 Bayview Ave MG408, Toronto, Ontario, M4N 3M5, Canada
    Curr Urol Rep 14:159-67. 2013
  9. doi Prostate cancer overdiagnosis and overtreatment
    Laurence Klotz
    University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Ave MG 408, Toronto, Ontario, Canada
    Curr Opin Endocrinol Diabetes Obes 20:204-9. 2013
  10. doi Active surveillance: patient selection
    Laurence Klotz
    Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Urol 23:239-44. 2013

Detail Information

Publications84

  1. ncbi Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Semin Radiat Oncol 18:2-6. 2008
    ..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed...
  2. ncbi What is the best approach for screen-detected low volume cancers?--The case for observation
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Urol Oncol 26:495-9. 2008
    ....
  3. ncbi Combined androgen blockade: an update
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Urol Clin North Am 33:161-6, v-vi. 2006
    ..This treatment must be balanced against the potential for an increase in side-effects and a consequent adverse effect on the patient's quality of life...
  4. ncbi Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 109:858-67. 2007
    ..Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone-refractory disease...
  5. doi Maximal androgen blockade for advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, ON, Canada
    Best Pract Res Clin Endocrinol Metab 22:331-40. 2008
    ..In prostate cancer patients at high risk for mortality (based on extent of disease or prostate-specific antigen kinetics), combination therapy with bicalutamide should be considered in preference to monotherapy...
  6. pmc Active surveillance for favorable-risk prostate cancer: a short review
    Nathan Lawrentschuk
    Department of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada
    Korean J Urol 51:665-70. 2010
    ....
  7. pmc Active surveillance for low-risk prostate cancer
    Laurence Klotz
    Department of Surgery, Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre 2075 Bayview Ave MG 408, Toronto Ontario M4N3M5
    F1000 Med Rep 4:16. 2012
    ..Like atypical small acinar proliferation, (ASAP), it may be managed with close follow up but without radical intervention, unless there is clear evidence of more aggressive disease...
  8. doi Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, 2075 Bayview Ave MG408, Toronto, Ontario, M4N 3M5, Canada
    Curr Urol Rep 14:159-67. 2013
    ....
  9. doi Prostate cancer overdiagnosis and overtreatment
    Laurence Klotz
    University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Ave MG 408, Toronto, Ontario, Canada
    Curr Opin Endocrinol Diabetes Obes 20:204-9. 2013
    ..The review also addresses the solutions to the problem of overdiagnosis and overtreatment, and summarizes the outcomes of these approaches...
  10. doi Active surveillance: patient selection
    Laurence Klotz
    Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Urol 23:239-44. 2013
    ..This is a summary of the current approach to patient selection for active surveillance, including eligibility criteria, current controversies and the role of imaging...
  11. doi A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leupr
    Laurence H Klotz
    Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Eur Urol 63:927-35. 2013
    ..We sought to determine whether a weekly dose of alendronate, an oral bisphosphonate, could reduce this unwanted side-effect...
  12. doi Active surveillance for prostate cancer: overview and update
    Laurence Klotz
    Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave MG 408, Toronto, M4N 3M5, Ontario, Canada
    Curr Treat Options Oncol 14:97-108. 2013
    ..Active surveillance is increasingly viewed as the management of choice for patients with very low-risk (low-grade, low-volume prostate cancer) and low-risk (low-grade but higher volume) disease...
  13. pmc Active surveillance: the Canadian experience with an "inclusive approach"
    Laurence Klotz
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, 2075 Bayview Ave, Toronto, Ontario
    J Natl Cancer Inst Monogr 2012:234-41. 2012
    ..Further studies are warranted to improve the identification of patients who harbor more aggressive disease in spite of favorable clinical parameters at diagnosis [reproduced from Klotz (1) with permission from Wolters Kluwer Health]...
  14. doi Cancer overdiagnosis and overtreatment
    Laurence Klotz
    Division of Urology, University of Toronto, Toranto, Ontario, Canada
    Curr Opin Urol 22:203-9. 2012
    ..Overdiagnosis has become a major problem in medicine in general and cancer in particular. This is a summary of this problem...
  15. doi Active surveillance: the Canadian experience
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Urol 22:222-30. 2012
    ..This article is a summary of the rationale, method, and results of active surveillance beginning in 1995 with the first prospective trial of this approach...
  16. doi Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes
    Laurence Klotz
    Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue MG408, Toronto, ON, M4N 3M5, Canada
    Curr Urol Rep 13:153-9. 2012
    ..This review article summarizes the evidence supporting active surveillance, and the current approach to this management strategy, including the roles of serial biopsy, PSA kinetics, and MR imaging...
  17. pmc Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4
    David Cervi
    1Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    BMC Cancer 10:258. 2010
    ..The purpose herein was to discover, validate and characterize functional biomarkers of dietary supplementation capable of suppressing the course of prostate cancer in vivo...
  18. ncbi Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202
    Laurence Klotz
    Sunnybrook Medical Center, Toronto, Ontario, Canada
    Eur Urol 58:313. 2010
    ..Based on surveillance studies, about 7% would be upgraded to Gleason 8-10 on rebiopsy [2]. Dutasteride also decreased the rate of urinary retention (1.6% vs 6.7%: a 77.3% relative reduction)...
  19. doi Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
    Laurence Klotz
    Department of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, MG408, Toronto, Ontario M4N 3M5 Canada
    J Clin Oncol 28:126-31. 2010
    ..Other-cause mortality accounted for almost all of the deaths. Additional studies are warranted to improve the identification of patients who harbor more aggressive disease despite favorable clinical parameters at diagnosis...
  20. doi Active surveillance for prostate cancer: a review
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, MG408, Toronto, ON, M4N 3M5, Canada
    Curr Urol Rep 11:165-71. 2010
    ..The rationale, patient selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed...
  21. ncbi Point: active surveillance for favorable risk prostate cancer
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, Ontario, Canada
    J Natl Compr Canc Netw 5:693-8. 2007
    ..This article reviews the results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention...
  22. ncbi Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
    Laurence Klotz
    Division of Urology, University of Toronto, and Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Curr Urol Rep 8:341-4. 2007
  23. doi Degarelix acetate for the treatment of prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Toronto, Ontario, Canada
    Drugs Today (Barc) 45:725-30. 2009
    ..Degarelix is currently available as a 1-month subcutaneous injection and has been approved for the treatment of advanced prostate cancer...
  24. ncbi Active surveillance for favorable-risk prostate cancer: who, how and why?
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue MG408, Toronto, ON M4N 3M5, Canada
    Nat Clin Pract Oncol 4:692-8. 2007
    ..The results of active surveillance, the criteria for patient selection and the appropriate thresholds for intervention are reviewed in this article...
  25. ncbi Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention
    Laurence Klotz
    University of Toronto, Canada
    Nat Clin Pract Urol 5:2-3. 2008
  26. ncbi Active surveillance for favorable risk prostate cancer: rationale, risks, and results
    Laurence Klotz
    University of Toronto Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Urol Oncol 25:505-9. 2007
    ..The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed...
  27. ncbi Active surveillance for favorable risk prostate cancer: rationale, results, and vis a vis focal therapy role
    L Klotz
    Sunnybrook Health Sciences Centre Toronto, ON, Canada
    Minerva Urol Nefrol 63:145-53. 2011
    ..We propose a complementary role for surveillance and focal therapy...
  28. ncbi Active surveillance for prostate cancer: a review
    Laurence Klotz
    Division of Urology, Professor of Surgery, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Ontario, Canada
    Arch Esp Urol 64:806-14. 2011
    ..In this review article, the rationale, criteria for patient selection, method of follow up, trigger for intervention, and results of active surveillance are reviewed...
  29. doi Active surveillance for prostate cancer: trials and tribulations
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, MG 408, Toronto, ON, M4N 3M5, Canada
    World J Urol 26:437-42. 2008
    ....
  30. ncbi Active surveillance versus radical treatment for favorable-risk localized prostate cancer
    Laurence Klotz
    Sunnybrook Health Sciences Center, University of Toronto, 2975 Bayview Avenue, MG408, Toronto, Ontario M4N 3M5, Canada
    Curr Treat Options Oncol 7:355-62. 2006
    ....
  31. doi The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, ON, Canada
    BJU Int 102:1531-8. 2008
    ....
  32. ncbi MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans
    Rajiv Chopra
    Imaging Research, Sunnybrook Research Institute, 2075 Bayview Ave, Room C713, Toronto, ON, Canada M4N 3M5
    Radiology 265:303-13. 2012
    ..To evaluate the feasibility and safety of magnetic resonance (MR) imaging-controlled transurethral ultrasound therapy for prostate cancer in humans...
  33. ncbi Intermittent androgen suppression in prostate cancer: the Canadian experience
    Antonio Hurtado-Coll
    Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Urology 60:52-6; discussion 56. 2002
    ..Intermittent therapy offers quality-of-life benefits during the off-therapy period, as well as reduced cost of treatment. This article will review the >15 years of Canadian experience with intermittent androgen suppression...
  34. doi A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies
    Stephane Supiot
    Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Radiother Oncol 88:53-60. 2008
    ..In a phase I trial, we investigated the feasibility of pre-operative radiotherapy for this patient subset...
  35. doi Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Urol 187:1247-52. 2012
    ..We report magnetic resonance imaging findings among unselected men with low risk prostate cancer before active surveillance...
  36. ncbi Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?
    Scott Bagnall
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Semin Oncol 30:587-95. 2003
    ..The outcome of a strategy of selective intervention in good-risk patients based on prostate-specific antigen (PSA) doubling time is summarized...
  37. ncbi Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation
    Peter S Bunting
    Department of Clinical Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Clin Biochem 35:471-5. 2002
    ..To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation...
  38. ncbi Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 107:389-95. 2006
    ..This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation...
  39. ncbi Variation in patterns of practice in diagnosing screen-detected prostate cancer
    Robert K Nam
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Canada
    BJU Int 94:1239-44. 2004
    ....
  40. ncbi Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience
    Antonio Hurtado-Coll
    Division of Urology, Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Urology 60:45-51; discussion 51. 2002
    ..In this article, we will review the Canadian experience, from the laboratory to the clinic...
  41. ncbi Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics
    Yonah Krakowsky
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 184:131-5. 2010
    ..This is a detailed report of 5 of 453 patients on surveillance who died of prostate cancer...
  42. doi MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies
    Kashif Siddiqui
    Department of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Urology 76:1506-11. 2010
    ..To confirm the correlation between planning and thermal injury of the prostate as determined by magnetic resonance imaging (MRI) and histology in canine and humans treated with transurethral ultrasound...
  43. ncbi Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma
    Richard Choo
    Toronto Sunnybrook Regional Cancer Center, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    BJU Int 94:295-8. 2004
    ..To assess the prostate specific antigen (PSA) doubling time of untreated, clinically localized, low-to-intermediate grade prostate carcinoma...
  44. doi Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance
    Andrew Loblaw
    Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 184:1942-6. 2010
    ..We determined the proportion of men with nonprogressive prostate cancer on active surveillance who had a trigger for treatment using various measures of prostate specific antigen kinetics...
  45. ncbi MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy
    Elizabeth Ramsay
    Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
    J Magn Reson Imaging 38:1564-71. 2013
    ....
  46. ncbi Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression
    Richard Choo
    Toronto Sunnybrook Regional Cancer Center and Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 167:1664-9. 2002
    ..We assessed the feasibility of a watchful waiting protocol with selective delayed intervention using clinical, prostate specific antigen (PSA) or histological progression as treatment indications for clinically localized prostate cancer...
  47. ncbi Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases
    Neil Fleshner
    Department of Urology Surgery, Toronto Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Urology 60:93-7. 2002
    ..Clinicians are commonly faced with the dilemma of elevating PSA levels despite negative prostate biopsy results in patients without symptoms of prostatitis...
  48. ncbi Modeling prostate specific antigen kinetics in patients on active surveillance
    Liying Zhang
    Division of Clinical Trials and Epidemiology, and Department of Radiation Oncology, and Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 176:1392-7; discussion 1397-8. 2006
    ..Prostate specific antigen doubling time was used to stratify patients into groups at low and high risk for progression. The prostate specific antigen kinetics in these 2 groups were modeled...
  49. pmc What can surrogate tissues tell us about the oxidative stress status of the prostate? A hypothesis-generating in-vivo study
    Kaitlyn F Whelan
    Department of Surgery, McMaster University, Hamilton, Ontario, Canada
    PLoS ONE 5:e15880. 2010
    ..We sought to determine if the individual's prostatic OS status can be determined by examining the OS in surrogate androgen regulated tissues from the same host...
  50. doi Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance
    Ross J Mason
    Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Eur Urol 59:863-7. 2011
    ..Among renal masses undergoing AS, some grow rapidly and require treatment or progress to metastatic disease. Patient and tumour characteristics related to this more aggressive behaviour have been poorly studied...
  51. doi Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet
    Min Hou
    Division of Urology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
    Biochem Biophys Res Commun 397:537-42. 2010
    ..These effects may explain its translational role relating to its anti-neoplastic potential...
  52. doi The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer
    Martin Gleave
    Department of Urology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
    Urol Oncol 27:81-6. 2009
    ..To summarize the debate regarding use of intermittent androgen suppression therapy in the treatment of prostate cancer originally presented at the 2007 Spring Meeting of the Society of Urologic Oncology...
  53. ncbi Active surveillance with selective delayed intervention for favorable risk prostate cancer
    Laurence Klotz
    Division of Urology, University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Urol Oncol 24:46-50. 2006
    ....
  54. ncbi Expectant management with selective delayed intervention for favorable risk prostate cancer
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5, Canada
    Urol Oncol 7:175-9. 2002
    ..In these patients, a policy of close monitoring with selective intervention for the 15-20% who progress rapidly is appealing. This approach is currently the focus of several clinical trials...
  55. ncbi Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Richard Choo
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 52:674-80. 2002
    ..To evaluate the efficacy of postoperative adjuvant radiotherapy (RT) for positive resection margin and/or pathologic T3 (pT3) adenocarcinoma of the prostate with undetectable postoperative prostate-specific antigen (PSA) levels...
  56. doi Gonadotropin-releasing hormone: an update review of the antagonists versus agonists
    Hein Van Poppel
    Department of Urology, University Hospitals Leuven, Belgium Division of Urology, University of Toronto, Toronto, Ontario, Canada
    Int J Urol 19:594-601. 2012
    ....
  57. ncbi Active surveillance for prostate cancer: for whom?
    Laurence Klotz
    University of Toronto, Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario M4N 3M5 Canada
    J Clin Oncol 23:8165-9. 2005
    ....
  58. ncbi Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer
    Laurence Klotz
    Department of Surgery, University of Toronto, Ontario, Canada
    J Urol 172:S48-50; discussion S50-1. 2004
    ..The challenge is to identify those patients who are not likely to experience significant progression, while offering radical therapy to those who are at risk...
  59. ncbi Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College, Health Sciences Centre, Toronto, ON, Canada
    Clin Prostate Cancer 2:106-10. 2003
    ....
  60. doi Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells
    Ahmed Q Haddad
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Nutr Cancer 62:668-81. 2010
    ..Other functional categories altered included chromosome organization, apoptosis, and stress response. These results demonstrate the multiple mechanisms of antitumor activity of DHC and fisetin in prostate cancer cells in vitro...
  61. ncbi Cardiovascular effects of androgen depletion and replacement therapy
    Jehonathan H Pinthus
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Urology 67:1126-32. 2006
  62. ncbi Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors
    Ryan Groll
    Department of Surgery Urology, Toronto Sunnybrook Regional Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Urology 59:551-4. 2002
    ..To determine the clinical value of assessing primary Gleason scoring among patients with grade 7 tumors at needle biopsy with emphasis on its correlation with final pathologic stage and grade...
  63. ncbi Dietary fat and prostate cancer
    Neil Fleshner
    Division of Urology and Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Canada
    J Urol 171:S19-24. 2004
    ..We provide a critical appraisal of the existing evidence for an association between dietary fat consumption and prostate cancer, and review the biologically plausible relationships...
  64. ncbi Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue MG 408, Toronto, Ontario, Canada M4N 3M5
    Eur Urol 47:16-21. 2005
    ....
  65. ncbi Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients
    Dennis Wagner
    Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
    J Clin Endocrinol Metab 98:1498-507. 2013
    ..Vitamin D3 might benefit prostate cancer (PCa) patients because prostate cells can locally synthesize the active hormone calcitriol...
  66. ncbi Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men
    David J A Jenkins
    Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, 61 Queen St East, Toronto, Ontario, Canada M5C 2T2
    J Urol 169:507-11. 2003
    ..Soy proteins used to lower serum cholesterol are rich sources of phytoestrogens. Therefore, we assessed the effect of soy consumption on serum PSA in men who had participated in cholesterol lowering studies...
  67. ncbi Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer
    Laurence Klotz
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
    Nat Clin Pract Urol 2:136-42; quiz 1 p following 149. 2005
    ..The results at 8 years were favorable. Longer follow-up will be required if the study is to confirm the safety of this approach in men with a long life expectancy (> 15 years)...
  68. doi Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback
    Rajiv Chopra
    Imaging Research, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Phys Med Biol 54:2615-33. 2009
    ..This study demonstrates the benefit of adaptive energy delivery using active MR temperature feedback, and an excellent capability to treat precise regions within the prostate gland with this technology...
  69. ncbi Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease
    Andrew H Feifer
    Department of Surgery, Division of Urology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    J Urol 168:150-4; discussion 154. 2002
    ..We also compared the amounts of active compound in different lots of the same brand to determine the consistency of the manufacturing process...
  70. pmc PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
    Laurence Klotz
    Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ont
    Can Urol Assoc J 1:17-21. 2007
    ..The consensus conference, which forms the basis for this report, attempted to develop an expert opinion, based on these studies, as to the optimal use of 5ARIs in patient management...
  71. pmc Feasibility and safety of silicone rubber contrast-enhanced microcomputed tomography in evaluating the angioarchitecture of prostatectomy specimens
    Alex K Yeung
    Department of Medical Imaging, Toronto General Hospital, Toronto, Ontario, Canada
    Transl Oncol 4:173-7. 2011
    ..The use of microCT on Microfil-injected prostates seems to be a feasible and specimen-preserving method for visualizing the three-dimensional vessel patterns present in resected human prostates...
  72. pmc Gleason grading controversies: what the chemoprevention trials have taught us
    Laurence Klotz
    Professor, Department of Surgery, University of Toronto, Toronto, ON
    Can Urol Assoc J 3:S115-20. 2009
    ..Re-evaluation of the results based on the pathology of the RP specimens and longer follow-up showed a 30% reduction in cancer incidence with finasteride and no significant differences in Gleason scores compared with placebo...
  73. doi Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2
    Kalathil Suresh
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
    Int J Oncol 39:907-13. 2011
    ..HER2 DC induced CTL lysed HER2+ HLA-A2+ tumor cells (MCF-7); significantly reduced lysis occurred in HER2+ HLA-A2- tumor cells (SKOV-3), and the NK cell sensitive cell line K-562...
  74. ncbi Critical evaluation of hormonal therapy for carcinoma of the prostate
    Gerald W Chodak
    Midwest Prostate and Urology Health Center, Chicago, Illinois 60640, USA
    Urology 60:201-8. 2002
  75. ncbi Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  76. ncbi Combined androgen blockade: the case for bicalutamide
    Laurence Klotz
    Sunnybrook and Women s College Health Sciences Centre University of Toronto, Canada
    Clin Prostate Cancer 3:215-9. 2005
    ..An analysis combining historic trial data suggests that bicalutamide 50 mg in addition to androgen deprivation may reduce the hazard ratio (HR) for prostate cancer mortality by 20% (HR, 0.80; 95% CI, 0.66-0.98)...
  77. ncbi [Reevaluation of MAB therapy and progress of endocrine therapy]
    Laurence Klotz
    Gan To Kagaku Ryoho 32:705-28. 2005
  78. ncbi Urothelial carcinoma of the prostate
    Juan Palou
    Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain
    Urology 69:50-61. 2007
    ..Prospective and multicenter trials are needed to identify the real incidence and the best management of these patients. In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer...
  79. ncbi Outcomes of treatment vs observation of localized prostate cancer in elderly men
    Mark C Scholz
    JAMA 297:1651-2; author reply 1652-3. 2007
  80. doi Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer
    Nicholas Bruchovsky
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, Canada
    Clin Genitourin Cancer 6:46-52. 2008
    ..Observations of quality of life (QOL), morbidity, and mortality were obtained from the results of a prospective phase II study of intermittent androgen suppression for recurrent prostate cancer after radiation therapy...
  81. doi Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  82. ncbi A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma
    Hendrik VAN Poppel
    Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Eur Urol 51:1606-15. 2007
    ....
  83. ncbi Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 172:S3-5. 2004
  84. doi An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
    Christopher Wood
    M D Anderson Cancer Center, Houston, TX, USA
    Lancet 372:145-54. 2008
    ....